赛默飞世尔发布保守利润指引，股价受挫

Core Viewpoint - The company has issued a conservative profit guidance for 2026, indicating that annual profits may fall below Wall Street expectations due to various external factors [1] Industry Policy and Environment - The U.S. government's budget cuts for academic research institutions are expected to continue until 2026, leading to cautious equipment procurement by downstream research clients and biotechnology companies [1] - The reduction in research funding by the Trump administration directly impacts the company's core customer base, suppressing short-term demand [1] - Increased competition pressure arises from U.S. trade policies and rising supply chain costs between the U.S. and China, particularly affecting the company's lower-margin businesses in the domestic mid-range market [1] Operating Conditions - Despite a significant rebound in demand from pharmaceutical clients in Q4 2025, high-end instrument equipment demand remains sluggish due to budget constraints faced by U.S. government and academic clients [2] - The analytical instruments business experienced an 11.2% year-over-year profit decline in 2025, reflecting growth pressures in this sector [2] Company Status - The company has announced the closure of its facilities in Franklin, Massachusetts, and Asheville, North Carolina, with plans to complete these adjustments by the end of 2026 [3] - These operational changes aim to optimize global efficiency and concentrate resources on higher-margin businesses, although they may incur restructuring costs and impact market confidence in the short term [3] Institutional Views - Some institutions, such as CMB International, maintain a "buy" rating, believing that long-term demand in biopharmaceuticals and strategic acquisitions will support competitiveness, despite concerns over weak short-term guidance [4]